Dose-Dense Sequential Adjuvant Chemotherapy with Epirubicin, Paclitaxel and CMF in High-Risk Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|60|3|214-220

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.3, 2001-04, pp. : 214-220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer

By  

Oncology, Vol. 78, Iss. 3-4, 2010-06 ,pp. : 271-273

Karger

Access to resources Recommend Favorite

Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy Is Well Tolerated and Safe in High-Risk Early Breast Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 446-453

Karger

Access to resources Recommend Favorite

Dose-Dense Adjuvant Chemotherapy with Epirubicin Monotherapy in Patients with Operable Breast Cancer and ≥10 Positive Axillary Lymph Nodes

By  

Oncology, Vol. 55, Iss. 6, 1998-10 ,pp. : 508-512

Karger

Access to resources Recommend Favorite

Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer

By  

Oncology, Vol. 69, Iss. 5, 2005-12 ,pp. : 372-383

Karger

Access to resources Recommend Favorite

A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52)

By  

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3639-3648

John Wiley & Sons Inc

Access to resources Recommend Favorite